Literature DB >> 23756547

A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis.

Hemang B Panchal1, Vatsal Ladia, Saurabh Desai, Tejaskumar Shah, Vijay Ramu.   

Abstract

The purpose of this meta-analysis was to compare postprocedural mortality and major adverse cardiovascular and cerebrovascular events between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) for severe aortic stenosis. Seventeen studies (n = 4,659) comparing TAVI (n = 2,267) and SAVR (n = 2,392) were included. End points were baseline logistic European System for Cardiac Operative Risk Evaluation score, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, transient ischemic attack, and major bleeding events. Mean differences or risk ratios with 95% confidence intervals were computed, and p values <0.05 were considered significant. The population was matched for risk between the 2 groups on the basis of logistic European System for Cardiac Operative Risk Evaluation score for all outcomes except 30-day all-cause mortality, which had a high-risk population in the TAVI group (p = 0.02). There was no significant difference found in all-cause mortality at 30 days (p = 0.97) and at an average of 85 weeks (p = 0.07). There was no significant difference in cardiovascular mortality (p = 0.54) as well as the incidence of myocardial infarction (p = 0.59), stroke (p = 0.36), and transient ischemic attack (p = 0.85) at averages of 86, 72, 66, and 89 weeks, respectively. Compared with patients who underwent TAVI, those who underwent SAVR had a significantly higher frequency of major bleeding events (p <0.0001) at mean follow-up of 66 weeks. In conclusion, TAVI has similar cardiovascular and all-cause mortality to SAVR at early and long-term follow-up. TAVI is superior to SAVR for major bleeding complications and noninferior to SAVR for postprocedural myocardial infarctions and cerebrovascular events. TAVI is a safe alternative to SAVR in selected high-risk elderly patients with severe aortic stenosis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23756547     DOI: 10.1016/j.amjcard.2013.05.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  3D Printed Cardiac Phantom for Procedural Planning of a Transcatheter Native Mitral Valve Replacement.

Authors:  Richard L Izzo; Ryan P O'Hara; Vijay Iyer; Rose Hansen; Karen M Meess; S V Setlur Nagesh; Stephen Rudin; Adnan H Siddiqui; Michael Springer; Ciprian N Ionita
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2016-04-05

2.  Contained aortic annulus rupture with persisting false aneurysm after transfemoral transcatheter aortic valve implantation.

Authors:  Stephanie Egenrieder; Stephan Hill; Maik Backes; Matthias Vöhringer; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2014-08       Impact factor: 5.460

3.  Management of Coronary Artery Disease and Conduction Abnormalities in Transcatheter Aortic Valve Implantation.

Authors:  Anna Kostopoulou; Panagiotis Karyofillis; Efthimios Livanis; George Karavolias; George Theodorakis; John Paraskevaides; Vassilis Voudris
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

4.  Redo aortic valve surgery versus transcatheter valve-in-valve implantation for failing surgical bioprosthetic valves: consecutive patients in a single-center setting.

Authors:  Magdalena Erlebach; Michael Wottke; Marcus-André Deutsch; Markus Krane; Nicolo Piazza; Ruediger Lange; Sabine Bleiziffer
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

5.  Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit.

Authors:  Stephanie M Meller; Andreas Baumbach; Szilard Voros; Michael Mullen; Alexandra J Lansky
Journal:  BMC Med       Date:  2013-12-11       Impact factor: 8.775

6.  Network meta-analysis on the comparative effectiveness and safety of transcatheter aortic valve implantation with CoreValve or Sapien devices versus surgical replacement.

Authors:  G Biondi-Zoccai; M Peruzzi; A Abbate; Z M Gertz; U Benedetto; E Tonelli; F D'Ascenzo; A Giordano; P Agostoni; G Frati
Journal:  Heart Lung Vessel       Date:  2014

7.  Effect of transcatheter aortic valve implantation on QT dispersion in patients with aortic stenosis.

Authors:  Hakan Erkan; Engin Hatem; Mustafa Tarık Ağaç; Levent Korkmaz; Teyyar Gökdeniz; Ahmet Çağrı Aykan; Ezgi Kalaycıoğlu; Faruk Boyacı; Ömer Faruk Çırakoğlu; Şükrü Çelik
Journal:  J Geriatr Cardiol       Date:  2014-12       Impact factor: 3.327

Review 8.  From CoreValve to Evolut PRO: Reviewing the Journey of Self-Expanding Transcatheter Aortic Valves.

Authors:  Dhruv Mahtta; Islam Y Elgendy; Anthony A Bavry
Journal:  Cardiol Ther       Date:  2017-10-27

Review 9.  Functional status and quality of life after transcatheter aortic valve replacement: a systematic review.

Authors:  Caroline A Kim; Suraj P Rasania; Jonathan Afilalo; Jeffrey J Popma; Lewis A Lipsitz; Dae Hyun Kim
Journal:  Ann Intern Med       Date:  2014-02-18       Impact factor: 25.391

10.  Impact of transcatheter aortic valve implantation on the risk of mortality in patients with severe aortic valve diseases: a health insurance-based analysis.

Authors:  Alexander Barth; Seyrani Yücel; Hüseyin Ince; Gabriele Doblhammer
Journal:  Open Heart       Date:  2018-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.